Premium
GATA ‐binding protein 3 enhances the utility of gross cystic disease fluid protein‐15 and mammaglobin A in triple‐negative breast cancer by immunohistochemistry
Author(s) -
Huo Lei,
Gong Yun,
Guo Ming,
Gilcrease Michael Z,
Wu Yun,
Zhang Hong,
Zhang Jinxia,
Resetkova Erika,
Hunt Kelly K,
Deavers Michael T
Publication year - 2015
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12645
Subject(s) - mammaglobin , immunohistochemistry , triple negative breast cancer , pathology , breast cancer , medicine , staining , cancer
Aims We have demonstrated previously that gross cystic disease fluid protein‐15 ( GCDFP ‐15) and mammaglobin A ( MAM ) are of limited utility in triple‐negative breast cancer ( TNBC ). GATA ‐binding protein 3 ( GATA ‐3) is an emerging breast‐associated immunohistochemical ( IHC ) marker with limited data in TNBC . Here, we examined GATA ‐3 expression in TNBC in comparison with GCDFP ‐15 and MAM . Methods and results We studied GATA ‐3, GCDFP ‐15 and MAM IHC expression in 62 primary and 68 metastatic TNBC s. In primary TNBC s, GATA ‐3 staining was observed in 25 cases (40%), including 16 cases that were negative for GCDFP ‐15 and MAM . In metastatic TNBC s, GATA ‐3 staining was observed in 30 cases (44%), including 16 cases that were negative for GCDFP ‐15 and MAM . The expression frequency of any of the markers was 56% in primary and 62% in metastatic TNBC s. However, when focal staining was excluded, the expression frequency of any marker dropped to 31% and 44%, respectively. Conclusion GATA ‐3 is expressed at a higher frequency by IHC in TNBC compared to GCDFP ‐15 and MAM , although the tissue specificity of the latter markers may be superior. When evaluating a triple‐negative tumour, including GATA ‐3 in a panel of markers may increase the diagnostic accuracy for tissue origin in the appropriate clinical setting.